Design of potent inhibitors of human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a chimera peptide.
Stasiak, Alicja Z
KAUST Grant NumberKUK-11-008-23
Online Publication Date2010-07-19
Print Publication Date2010-08-12
Permanent link to this recordhttp://hdl.handle.net/10754/596780
MetadataShow full item record
AbstractWe have previously shown that a 28-amino acid peptide derived from the BRC4 motif of BRCA2 tumor suppressor inhibits selectively human RAD51 recombinase (HsRad51). With the aim of designing better inhibitors for cancer treatment, we combined an in silico docking approach with in vitro biochemical testing to construct a highly efficient chimera peptide from eight existing human BRC motifs. We built a molecular model of all BRC motifs complexed with HsRad51 based on the crystal structure of the BRC4 motif-HsRad51 complex, computed the interaction energy of each residue in each BRC motif, and selected the best amino acid residue at each binding position. This analysis enabled us to propose four amino acid substitutions in the BRC4 motif. Three of these increased the inhibitory effect in vitro, and this effect was found to be additive. We thus obtained a peptide that is about 10 times more efficient in inhibiting HsRad51-ssDNA complex formation than the original peptide.
CitationNomme J, Renodon-Cornière A, Asanomi Y, Sakaguchi K, Stasiak AZ, et al. (2010) Design of Potent Inhibitors of Human RAD51 Recombinase Based on BRC Motifs of BRCA2 Protein: Modeling and Experimental Validation of a Chimera Peptide. Journal of Medicinal Chemistry 53: 5782–5791. Available: http://dx.doi.org/10.1021/jm1002974.
SponsorsWe thank Drs. Fabrice Fleury and Pierre Weigel for discussions and Dr. Kyoko Iwasaki-Yoshikane for CD measurements. This work was supported by grants from the Association pour la Recherche sur le Cancer [no. 3862], the Région de Pays de la Loire [MIAPS] and [CIMATH], the King Abdullah University of Science and Technology [KUK-11-008-23 to B.N.], and Swiss National Science Foundation [31003A-116275 to A.S.]. J.N. is a recipient of a Ph.D. fellowship from the Ligue Contre le Cancer Comité Loire Atlantique.
PublisherAmerican Chemical Society (ACS)
JournalJournal of Medicinal Chemistry
PubMed Central IDPMC2917172
CollectionsPublications Acknowledging KAUST Support
- Inhibition of filament formation of human Rad51 protein by a small peptide derived from the BRC-motif of the BRCA2 protein.
- Authors: Nomme J, Takizawa Y, Martinez SF, Renodon-Cornière A, Fleury F, Weigel P, Yamamoto K, Kurumizaka H, Takahashi M
- Issue date: 2008 May
- Interrogation of the protein-protein interactions between human BRCA2 BRC repeats and RAD51 reveals atomistic determinants of affinity.
- Authors: Cole DJ, Rajendra E, Roberts-Thomson M, Hardwick B, McKenzie GJ, Payne MC, Venkitaraman AR, Skylaris CK
- Issue date: 2011 Jul
- Design, synthesis, and characterization of BRC4 mutants based on the crystal structure of BRC4-RAD51(191-220).
- Authors: Zhao D, Lu K
- Issue date: 2015 Nov
- Interaction between Arabidopsis Brca2 and its partners Rad51, Dmc1, and Dss1.
- Authors: Dray E, Siaud N, Dubois E, Doutriaux MP
- Issue date: 2006 Mar
- Cancer-associated mutations in BRC domains of BRCA2 affect homologous recombination induced by Rad51.
- Authors: Tal A, Arbel-Goren R, Stavans J
- Issue date: 2009 Nov 13